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Abstract
Objective
To test the hypothesis that antidrug antibodies (ADAs) against alemtuzumab could become
relevant after repeated treatments for some individuals, possibly explaining occasional treat-
ment resistance.
Methods
Recombinant alemtuzumab single-chain variable fragment antibody with a dual tandem
nanoluciferase reporter linker was made and used to detect binding ADAs. Alemtuzumab
immunoglobulin G Alexa Fluor 488 conjugate was used in a competitive binding cell-based
assay to detect neutralizing ADAs. The assays were used to retrospectively screen, blinded,
banked serum samples from people with MS (n = 32) who had received 3 or more cycles of
alemtuzumab. Lymphocyte depletion was measured between baseline and about 1 month
postinfusion.
Results
The number of individuals showing limited depletion of lymphocytes increased with the
number of treatment cycles. Lack of depletion was also a poor prognostic feature for future
disease activity. ADA responses were detected in 29/32 (90.6%) individuals. Neutralizing
antibodies occurred before the development of limited depletion in 6/7 individuals (18.8% of
the whole sample). Preinfusion, ADA levels predicted limited, postinfusion lymphocyte
depletion.
Conclusions
Although ADAs to alemtuzumab have been portrayed as being of no clinical significance,
alemtuzumab-specific antibodies appear to be clinically relevant for some individuals, although
causation remains to be established. Monitoring of lymphocyte depletion and the antidrug
response may be of practical value in patients requiring additional cycles of alemtuzumab. ADA
detection may help to inform on retreatment or switching to another treatment.
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MS is an immune-mediated, demyelinating disease of the
CNS. Memory T and B lymphocytes are key in the patho-
physiology of MS, and these cell types are targeted by an
increasing number of disease-modifying treatments (DMTs)
capable of inhibiting relapsing MS. These DMTs are admin-
istered continuously or given as a pulsed immune re-
constitution therapy to produce long-term disease inhibition.1
Alemtuzumab was the first biological immune reconstitution
therapy licensed for the treatment of people with MS
(PwMS).1,2 This depletes lymphocytes in vivo and in vitro by
a number of mechanisms, including complement fixation and
antibody-dependent cellular cytotoxicity,1,2 and has been
shown to be highly efficacious in suppressing relapses in
PwMS (Comparison of Alemtuzumab and Rebif Efficacy in
Multiple Sclerosis Study One and Two [CARE MS I and
II]).3,4 However, a small number of people appear to be un-
responsive to alemtuzumab and continue to experience clin-
ical relapses despite treatment.5
Although alemtuzumab was the first humanized mono-
clonal antibody engineered with the aim of reducing im-
munogenicity to the founding rodent molecule,6
surprisingly, it is one of the most immunogenic therapeutic
proteins7,8 generating antidrug antibodies (ADAs), which
may be either binding or neutralizing.8 Yet, these have
been reported to be of minimal clinical significance.9–11
Indeed, the dosing schedule of alemtuzumab9–12 avoids
issues of ADA, which occur with high frequency (;85%)
within 2 years of treatment.13–15 Using the currently rec-
ommended treatment schedule, the infusion cycle ends
before primary and secondary antibody responses will be
generated, and the recommended interval of at least 12
months between treatment cycles allows ADA levels to
subside.7,13 Neutralizing ADAs were not mentioned in the
pivotal trial reports.10–12 These only occurred in 0.6% of
PwMS before the second infusion cycle,7 so would be in-
frequently problematic within the original 2-year treat-
ment cohort.1,10,11 However, as additional treatment
cycles were shown to be efficacious in people not ade-
quately responding to 2 cycles,3,4,15 the European Medi-
cines Agency supported the use of third and fourth
treatment cycles in 2017. However, predose binding and
neutralizing ADA become far more prevalent following the
second treatment cycle (75% and 31% at 24 months, re-
spectively), a factor which may limit the biological and
clinical efficacy of the subsequent treatment cycles.7,8 In
this study, we investigated the hypothesis that ADAs be-
come increasingly problematic after successive cycles of
alemtuzumab treatment and that the ADA levels may be
associated with diminished treatment effectiveness.
Methods
ADA assays
To monitor PwMS in our care, we developed an in-house
luminescence-based, antiglobulin detection assays for
binding anti–alemtuzumab-specific antibodies.16 In brief,
a recombinant single-chain variable fragment based on
alemtuzumab variable heavy and light chains was engi-
neered as a fusion protein with 2 nanoluciferase reporter
domains (GloBody). In the presence of ADAs, GloBody-
ADA complexes form which are captured on immobilized
protein-G and the retained luciferase activity measured.16 In
addition, competitive binding of Alexa Fluor 488–labeled
alemtuzumab to adherent human CD52-expressing Chinese
hamster ovary cells, coupled with serial dilutions of serum,
was used as a neutralizing assay.17 Detailed methodology
has been reported previously.16,17
Ethical approval
Samples were collected with informed consent and ethical
approval (Research Ethics Committee approval references:
19/WA/0058 and 05/WSE01/11).
Alemtuzumab treatment
People received 5 daily 12 mg infusions at baseline and 3
daily 12 mg infusions where administered 12 months
later11. Following disease activity (typically ≥1 relapse and/
or ≥2 unique lesions defined as either new/enlarging T2
hyperintense and/or gadolinium-enhancing brain and/or
spinal cord lesions via MRI), additional cycles of 3 daily
12 mg infusions could be administered at least 12 months
apart.3,4
Samples
The assays were applied to bioarchived serum samples
from 32 PwMS who had all received 3 or more cycles of
alemtuzumab.5 Samples were obtained from the Welsh
Neuroscience Research Tissue Bank (WNRTB) and had
been donated as part of a long-running population study of
MS, which has previously been described.18 Analysis of
ADA was performed blinded to clinical and laboratory data
from the WNRTB. Individuals had received 3 (n = 24), 4
(n = 3), 5 (n = 4), or 6 (n = 1) cycles of alemtuzumab.
Absolute lymphocyte counts, taken from routine labora-
tory reports where available, from time points immediately
before, and 1–2 month after each infusion, were used to
calculate relative depletion rates. Apparent lymphocyte
depletion was defined as ≥ 35% reduction in
absolute lymphocyte count pre- to postinfusion and/or
depletion below the lower limit of normal.
Glossary
ADA = antidrug antibody; DMT = disease-modifying treatment; EDSS = Expanded Disability Status Scale; PwMS = people
with MS; WNRTB = Welsh Neuroscience Research Tissue Bank.
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Statistical analysis
Statistical analysis was performed using the t test/Mann-
Whitney U tests using Sigmaplot Software (Systat, San
Jose, CA).
Data sharing
Anonymous data are available on request.
Results
Cohort characteristics
At the time of sample requisition from the WNRTB, 137
people had received alemtuzumab within the South Wales
cohort. In total, 40 people had received 3 or more treatment
cycles of alemtuzumab. The rates of receiving a third (or
subsequent treatment) in this cohort was 49% (39/80) of
people followed up to 5 years and 50% (15/30) of people
followed up to 10 years. Archived blood samples were avail-
able from 32 of the total 40 individuals who had ever received
a third cycle of treatment. The 32 people who had donated
blood samples were 28 female (88%) and had a mean age at
MS onset of 29 years (range 10–44 years). All PwMS received
alemtuzumab as first-line treatment; the first cycle was ad-
ministered after a mean duration of 4.5 years (range 0.6–17
years) from symptom onset.
Individuals do not deplete lymphocytes on
repeated infusion of alemtuzumab
Lymphocyte depletion data were available for 32 of 32 (cycle
1), 32 of 32 (cycle 2), and 31 of 32 (cycle 3). At the population
level, lymphocyte depletion was marked and significant (p <
0.001) compared with precycle treatment levels for cycle 1 to
cycle 3 (figure 1). However, at an individual level, 31 of 32
people (97%) showed apparent lymphocyte depletion follow-
ing cycle 1, 30 of 32 (94%) after cycle 2, and 27 of 31 (87%)
after cycle 3 in PwMS (figure 1). Of the 4 people who did not
show apparent lymphocyte depletion after cycle 3, 2 had pre-
viously shown limited depletion after cycle 2. Lymphocyte
subset analysis was not available. Although it is recognized that
these counts will reflect a composite of depleted and repopu-
lating cells,7 whose composition may change due to the dif-
ferent reconstitution kinetics of distinct lymphocyte subsets,7
relative lack of depletion may be an indicator for the lack of
efficacy of alemtuzumab due to antibody neutralization.
ADA responses occur with high frequency
Baseline serum samples were available for 17/32 PwMS.
Using a binding ADA assay,16 low titers 751 ± 1,399 Lux were
evident in subjects before the first infusion (figure 2). How-
ever, 29/32 (90.6%) people generated binding ADA with
a titer > 2 SDs above the baseline mean (>3,549 Lux) during
their subsequent follow-up (figure 2). Some people demon-
strated very high ADA titers (mean 1,288,805 ± 2,773,146
Lux with a range 1,296–9,965,386 Lux) following alemtuzu-
mab treatment (figures 2 and 4). A standard monoclonal anti-
alemtuzumab immunoglobulin G (Bio-Rad HCA-199) spiked
into control serum at;50 μg/mL generated a signal of 21,159
± 6,468 Lux. The maximum blood concentration range of
alemtuzumab immediately after the third infusion is 2.3 ±
0.8 μg/mL14; ADA values in the range of the spiked standard
would be theoretically at least 16-fold molar excess of the
circulating levels of the drug.
Relationship between lymphocyte depletion,
ADAs, and treatment response
ADAs were clearly present in 6/7 individuals before poor
depletion occurred. Binding ADA titers were boosted with
each cycle of treatment, and the binding ADA became per-
sistent in some individuals (figure 3, A–D). This was associ-
ated with increasing levels of antibody neutralization (figure 3,
A–D). One individual appeared to demonstrate
limited lymphocyte depletion despite an absence of neutral-
izing ADA (figure 3E). However, in this case, month 1
Figure 1 Lymphocyte depletion following alemtuzumab treatment
PwMS received 3 cycles (n = 31). Few of these individuals
received 4 cycles (n = 7) of alemtuzumab. The figures rep-
resent the mean and SD of absolute peripheral blood lym-
phocyte count and the individual levels before and after
treatment for each treatment cycle. Those with depletion
that perhaps suggests atypical/insufficient (low change or
absolute depletion level above the lower limit of normal)
depletion (red) compared with those depleting (gray) are
indicated. In some individuals (black filled star), postdose
blood counts were more than 2 months from infusion. Sta-
tistical analysis was performed using the t test/Mann-Whit-
ney U tests. PwMS = people with MS.
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postinfusion lymphocyte data were unavailable. Lymphocyte
levels were first measured more than 2.5 months postinfusion,
so we cannot exclude the possibility that depletion, followed by
rapid repletion, occurred within this time window. Six of 7
individuals who depleted poorly exhibited disease activity within
2 years of infusion. In contrast, it was evident that only 13/28
PwMS with apparent lymphocyte depletion demonstrated dis-
ease activity after 3 cycles, with 14/16 people without disease
activity having >5 years of follow-up. People receiving 4 cycles
(figure 3 n = 7/7) of alemtuzumab subsequently exhibited
disease activity in this cohort. This study was not designed to
monitor the clinical significance of antibody neutralization.
However, when comparing baseline and 5-year Expanded Dis-
ability Status Scale (EDSS) scores, those who neutralized the
alemtuzumab response after 3 cycles of treatment showed
a median 1.0 point EDSS worsening (range 0.5–2.0, n = 5),
whereas those who did not develop neutralizing antibodies
showed a median improvement of 0.5 EDSS points (range −2.0
to 2.5, n = 26). This may suggest that antibody neutralization
has clinical significance, but further studies are warranted.
Predose ADA responses may detect
subsequent lymphocyte depletion responses
As it is known that most people generate ADA that wanes over
time (figure 3, B–D),7,8,14 precycle ADA levels and the
subsequent lymphocyte depletion level will be most informative
on the significance of ADA.7,8 However, only 23 serum samples
from 19 different individuals with lymphocyte depletion data
were taken less than 2 months before infusion. This included 5
predose samples from poor-depleting individuals whose ADA
titers were 2.7 × 104, 2.8 × 104, 8.9 × 104, 1.2 × 105, and 1.0 × 106
Lux units (figure 3). Many people who depleted lymphocytes
exhibited low-titer (below 1.5 × 103 Lux units) antibody
responses (figure 4A); however, there were individuals who had
relatively high titers (5.8 × 104 and 1.1 × 105 Lux units) of
binding ADA but exhibited notable depletion (1.4–0.2, 1.8 to
0.4 cells 109/L. Figure 4A) and did not relapse for at least 4 and
7 years after infusion. However, these individuals did not exhibit
neutralizing potential (figure 4, B and C). Therefore, binding
(<15,000 Lux) and neutralizing (≥10 titer for virtually complete
neutralization) titers perhaps could be adopted to suggest poor
depleters and depleters (figure 4A). It remains to be established
whether this can be applied prospectively, but the data suggest
that it is possible that predose ADA titer limits may be set that
can exclude potential futile treatments.
Discussion
Alemtuzumab is a potent immune reconstitution therapy;
however, up to 40%–50% of people receiving alemtuzumab for
MS require 3 or more cycles of treatment.5,15 Third and sub-
sequent cycles are often followed by a sustained remission of
disease activity,4,15 but cases are recognized to occur where
people are unresponsive to alemtuzumab and continue to ex-
perience clinical relapses despite treatment. During the clinical
development of alemtuzumab, the effect of neutralizing anti-
bodies was not mentioned, and ADAs have been repeatedly
portrayed as being clinically insignificant.11,12,19
However, our study suggests that some people develop persistent
neutralizing antibody responses to alemtuzumab and that this is
associated with limited lymphocyte depletion and disease activity.
Although it is not possible to prove cause and effect, it seems likely
that high-titer neutralizing responses would blunt or inhibit
the lymphocyte depletion response. In this study, 6/32 (18.8%)
developed high titers of both binding and neutralizing ADAs and
showed subsequent evidence of relative lack of lymphocyte de-
pletion. This is aligned with other reports in the literature of
disease activity requiring further infusions associated with lack
of lymphocyte depletion, which prompts switching to another
DMT.20 However, there are alternative explanations to ex-
plain poor depletion and disease breakthrough, such as alemtu-
zumab treatment leading to the emergence of CD52-
negative lymphocytes.21,22 This may have contributed to poor
depletion despite limited ADA response in 1 individual. Fur-
thermore, pharmacogenomics, such as Fc receptor genetic var-
iants, linking to antibody-dependent cellular cytotoxicity,may also
be relevant, particularly if antibody titers become limiting.1,23–25
Although the precise molecular mechanisms that cause the
formation of ADA remain to be defined, it is evident that the
majority of people produce CD52-specific ADA following
alemtuzumab infusion.7,13 This probably relates to a number
of factors that include the dose, dosing schedule, biology of
alemtuzumab, CD52 expression profile, and the repopulation
kinetics of ADA forming cells and CD52-expressing regula-
tory subsets.26 These ADAs are boosted with an increasing
number of infusions such that they become relatively persis-
tent in some individuals.7,13 Further prospectively collected
Figure 2 High-titer ADAs develop in most people following
alemtuzumab treatment
Alemtuzumab GloBody was used to detect binding ADA in sera from PwMS
who had received alemtuzumab. The results show individual baseline
responses before the initial infusion (blue; n = 17), the response to a 50 μg/
mL alemtuzumab ADA monoclonal antibody standard (Bio-Rad HCA-199,
green; n = 32), and the highest titer for each individual (red; n = 32) in any of
4–6 samples/individual banked during treatment. The mean ± SD group
scores are shown. ADA = antidrug antibody; PwMS = people with MS.
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Figure 3 Alemtuzumab neutralizing responses appear before PwMS apparently fail to deplete lymphocytes
The (A.a–E.a) binding and (A.b–E.b) neutralizing responses of 5 individuals treated with alemtuzumab. (A.a–E.a) The results show the time of the beginning of
each alemtuzumab infusion cycle, the absolute lymphocyte numbers, and the binding ADA titer or the neutralizing responses. (A.a–E.a) Lower limit of normal
of lymphocyte number (dashed line). In (A.b–E.b), samples 1–6 or 1–4 are from the same individual at sequential time points during follow-up. Year 0 indicates
1 January of the year of the initial dosing and the time of treatments and sampling during the year are indicated. ADA = antidrug antibody; PwMS = peoplewith
MS.
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data may help to validate and extend our findings and identify
the important perturbations of the immune networks that
facilitate ADA formation.7 Importantly, reevaluation of sam-
ples and data fromCARE-MS and their extension studies,7,8,19
which contains immunophenotyping and ADA data,7 may
provide further valuable insights into the relationship between
both binding and neutralizing (inhibitory) antibody titers and
the associated laboratory/clinical data. This may be particu-
larly enhanced if events within lymphoid tissues can be also
monitored, as they are the probably the source of ADA-
forming cells and are likely to deplete and repopulate differ-
ently to the peripheral blood.27,28 Previous reports of a lack of
association between ADA and lymphocyte depletion at the
population level10,12,15 are misleading because population
analyses are insensitive to low frequency events, as demon-
strated here. The influence of neutralizing ADAs alone has yet
to be reported from the pivotal trial extension data, but people
with the highest quartile of predose ADA producers deplete
their lymphocytes postdose less efficiently than people in the
lower 75% percentile,19 and suggests that analysis of the
neutralizing response may be informative for treatment re-
sponse in some individuals. Therefore, the neutralizing ADA
data from the pivotal trial extension studies should be
reported. Future work may also further define levels of ADAs
that are predictive of disease activity.
The lack of general awareness of the potential of alemtuzumab
to induce neutralizing antibodies, coupled with the sugges-
tion that disease activity is not related to lymphocyte levels,29
may contribute to viewing lymphocyte depletion data as being
unimportant. However, a failure of lymphocyte depletion is
likely to imply that alemtuzumab is less effective. Once an
individual failed to deplete, this was often seen in subsequent
treatment cycles. Although it will be the case that only a small
Figure 4 Alemtuzumab binding and neutralizing responses in people treated with alemtuzumab to predict treatment
response
Alemtuzumab GloBody and alemtuzumab Alexa Fluor 488 conjugates were used to detect (A) a combination of binding and neutralizing ADA or (B–D)
neutralizing ADA in sera from PwMS who had received alemtuzumab. (A) The binding ADA response in individual samples taken within 2 months before
infusion and the level of lymphocyte depletion within 2 months postinfusion compared with the preinfusion level from cycles 1–4. The neutralizing response
was tested in individuals with a binding ADA level <15,000 lux (green) and >15,000 lux (red and blue). Those with a titer above a 1:10 serum dilution that
essentially completely neutralized the alemtuzumab Alexa Fluor 488 binding response are indicated (red). Poor depleters were classified, before analysis, as
those exhibiting less than a 0.4 × 109 cells/L depletion. Individuals with high-titer binding ADA who depleted peripheral blood lymphocytes (blue) were found
(B and C) to lack notable neutralizing ADA responses, seen in individuals exhibiting poor depletion (red. 4D). ADA = antidrug antibody; PwMS=peoplewithMS.
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subset of lymphocytes will be clinically important and these will
not be accurately monitored by simply measuring lymphocyte
numbers, a lack of absolute lymphocyte depletion should
prompt extra vigilance.
Our study provides important preliminary data that pre-
infusion binding ADA titers >15,000 and/or complete neu-
tralization at >10 fold dilution may be associated with poor
postinfusion lymphocyte depletion. Furthermore, this appears to
be a predictor for future disease activity and the need for further
alemtuzumab infusions. Therefore, monitoring ADA before the
second or subsequent infusion cycles may be valuable in guiding
treatment decisions. The ADA detection technology used here
could also be applied to other monoclonal antibody treatments
to inform whether to retreat or to switch therapy. Identifying
people who are at risk of ineffective treatment responses might
save them from undergoing an expensive and futile treatment
and ensure cost-effective use of alemtuzumab.
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